ResearcherHospital Sírio-LibanêsNo recent work listed

Gustavo dos Santos Fernandes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3426-2167; OpenAlex author ID A5009974709. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper

Papers 3

Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases. Last author DOI 10.1007/s12029-020-00556-z ↗
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? Last author DOI 10.1007/s12029-018-0166-4 ↗
Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? Co-author DOI 10.1136/esmoopen-2019-000537 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Allan Andresson Lima Pereira · 1 shared paper, 2019 · strength 0.20
- Paper Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? DOI 10.1136/esmoopen-2019-000537 ↗
Camila Bragança Xavier · 1 shared paper, 2021 · strength 0.17
- Paper Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detai… DOI 10.1007/s12029-020-00556-z ↗
Daniel M. Girardi · 1 shared paper, 2019 · strength 0.11
- Paper Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? DOI 10.1007/s12029-018-0166-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.